Top

Published in:

01-12-2020 | Alzheimer's Disease | Research

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

Authors: Sanka Amadoru, Vincent Doré, Catriona A. McLean, Fairlie Hinton, Claire E. Shepherd, Glenda M. Halliday, Cristian E. Leyton, Paul A. Yates, John R. Hodges, Colin L. Masters, Victor L. Villemagne, Christopher C. Rowe

Published in: Alzheimer's Research & Therapy | Issue 1/2020

Abstract

Background

The Centiloid scale was developed to standardise the results of beta-amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD sparse and moderate-density neuritic plaques, Alzheimer’s disease neuropathologic change (ADNC) score of intermediate or high probability of Alzheimer’s Disease (AD), final clinicopathological diagnosis of AD, and expert visual read of a positive Aβ PET scan.

Methods

Aβ PET results in CL for 49 subjects were compared with post-mortem findings, visual read, and final clinicopathological diagnosis. The Youden Index was used to determine the optimal CL thresholds from receiver operator characteristic (ROC) curves.

Results

A threshold of 20.1 CL (21.3 CL when corrected for time to death, AUC 0.97) yielded highest accuracy in detecting moderate or frequent plaque density while < 10 CL was optimal for excluding neuritic plaque. The threshold for ADNC intermediate or high likelihood AD was 49.4 CL (AUC 0.98). Those cases with a final clinicopathological diagnosis of AD yielded a median CL result of 87.7 (IQR ± 42.2) with 94% > 45 CL. Positive visual read agreed highly with results > 26 CL.

Conclusions

Centiloid values < 10 accurately reflected the absence of any neuritic plaque and > 20 CL indicated the presence of at least moderate plaque density, but approximately 50 CL or more best confirmed both neuropathological and clinicopathological diagnosis of Alzheimer’s disease.

Available only for authorised users

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1–13. https://doi.org/10.1016/j.jalz.2011.10.007.CrossRefPubMedPubMedCentral

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. https://doi.org/10.1016/S1474-4422(14)70090-0.CrossRefPubMed

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRefPubMedPubMedCentral

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66:60–7. https://doi.org/10.1001/archneurol.2008.511.CrossRefPubMedPubMedCentral

Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013;34:822–31. https://doi.org/10.1016/j.neurobiolaging.2012.06.014.CrossRefPubMed

Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19:1044–51. https://doi.org/10.1038/mp.2014.9.CrossRefPubMedPubMedCentral

Beckett TL, Webb RL, Niedowicz DM, Holler CJ, Matveev S, Baig I, et al. Postmortem Pittsburgh compound B (PiB) binding increases with Alzheimer's disease progression. J Alzheimers Dis. 2012;32:127–38. https://doi.org/10.3233/JAD-2012-120655.CrossRefPubMedPubMedCentral

Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13–26. https://doi.org/10.1007/s40336-015-0102-6.CrossRefPubMedPubMedCentral

Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55:1623–8. https://doi.org/10.2967/jnumed.114.142109.CrossRefPubMed

10.

Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880–6. https://doi.org/10.2967/jnumed.112.114785.CrossRefPubMed

11.

Schonecker S, Prix C, Raiser T, Ackl N, Wlasich E, Stenglein-Krapf G, et al. Amyloid positron-emission-tomography with [18 F]-florbetaben in the diagnostic workup of dementia patients. Nervenarzt. 2017;88:156–61. https://doi.org/10.1007/s00115-016-0249-z.CrossRefPubMed

12.

Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9:e-1–16. https://doi.org/10.1016/j.jalz.2013.01.002.CrossRef

13.

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1–15 e1–4. https://doi.org/10.1016/j.jalz.2014.07.003.CrossRefPubMed

14.

Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26:8–16. https://doi.org/10.1097/WAD.0b013e31821300bc.CrossRefPubMedPubMedCentral

15.

Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78. https://doi.org/10.1016/S1474-4422(12)70142-4.CrossRef

16.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11:964–74. https://doi.org/10.1016/j.jalz.2015.02.004.CrossRef

17.

Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Performance of [(18)F] flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimers Dement (Amst). 2017;9:25–34. https://doi.org/10.1016/j.dadm.2017.06.001.CrossRef

18.

Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287–94. https://doi.org/10.1001/jamaneurol.2014.4144.CrossRef

19.

Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain. 2016;139:2540–53. https://doi.org/10.1093/brain/aww160.CrossRefPubMedPubMedCentral

20.

Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16:435–44. https://doi.org/10.1016/S1474-4422(17)30077-7.CrossRefPubMedPubMedCentral

21.

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement. 2018; https://doi.org/10.1016/j.jalz.2018.09.001.CrossRef

22.

Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018; https://doi.org/10.1016/j.jalz.2018.06.1353.CrossRef

23.

Dore V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, et al. Comparison of (18)F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL((R)) approaches: validation against histopathology. Alzheimers Dement. 2019;15:807–16. https://doi.org/10.1016/j.jalz.2019.02.005.CrossRefPubMed

24.

Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Members of the Familial Alzheimer's Disease Pathology Study G. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol. 2001;158:2165–75.CrossRef

25.

Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174–84. https://doi.org/10.1523/JNEUROSCI.0730-07.2007.CrossRefPubMedPubMedCentral

26.

Tan RH, Kril JJ, Yang Y, Tom N, Hodges JR, Villemagne VL, et al. Assessment of amyloid beta in pathologically confirmed frontotemporal dementia syndromes. Alzheimers Dement (Amst). 2017;9:10–20. https://doi.org/10.1016/j.dadm.2017.05.005.CrossRef

27.

Leyton CE, Villemagne VL, Savage S, Pike KE, Ballard KJ, Piguet O, et al. Subtypes of progressive aphasia: application of the international consensus criteria and validation using beta-amyloid imaging. Brain. 2011;134:3030–43. https://doi.org/10.1093/brain/awr216.CrossRefPubMed

28.

Rowe CC, Dore V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44:2053–9. https://doi.org/10.1007/s00259-017-3749-6.CrossRefPubMedPubMedCentral

29.

Rowe CC, Jones G, Dore V, Pejoska S, Margison L, Mulligan RS, et al. Standardized expression of 18F-NAV4694 and 11C-PiB beta-amyloid PET results with the Centiloid scale. J Nucl Med. 2016;57:1233–7. https://doi.org/10.2967/jnumed.115.171595.CrossRefPubMed

30.

Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159–66. https://doi.org/10.1016/j.neurobiolaging.2014.04.033.CrossRefPubMed

31.

Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, et al. MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS One. 2014;9:e84777. https://doi.org/10.1371/journal.pone.0084777.CrossRefPubMedPubMedCentral

32.

Bourgeat P, Dore V, Fripp J, Ames D, Masters CL, Salvado O, et al. Implementing the centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL. Neuroimage. 2018;183:387–93. https://doi.org/10.1016/j.neuroimage.2018.08.044.CrossRefPubMed

33.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–86.CrossRef

34.

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1–11. https://doi.org/10.1007/s00401-011-0910-3.CrossRefPubMed

35.

Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol. 2013;41:11–8. https://doi.org/10.2967/jnumed.110.076315.CrossRefPubMed

36.

Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 2008;50:419–30. https://doi.org/10.1002/bimj.200710415.CrossRefPubMedPubMedCentral

37.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. https://doi.org/10.1016/S1474-4422(13)70044-9.CrossRefPubMed

38.

Ikonomovic MAE, Price J, Mathis M, Klunk W. Evaluation of cotton wool plaques using amyloid binding compounds and Aβ immunohistochemistry: implications for PiB PET imaging. (abst). Human Amyloid Imaging Handbook; 2014. p. 41.

Title: Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
Authors: Sanka Amadoru
Vincent Doré
Catriona A. McLean
Fairlie Hinton
Claire E. Shepherd
Glenda M. Halliday
Cristian E. Leyton
Paul A. Yates
John R. Hodges
Colin L. Masters
Victor L. Villemagne
Christopher C. Rowe
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Alzheimer's Disease
Positron Emission Tomography
Alzheimer's Disease
Published in: Alzheimer's Research & Therapy / Issue 1/2020
Electronic ISSN: 1758-9193
DOI: https://doi.org/10.1186/s13195-020-00587-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET

The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer’s disease

Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase

Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study

Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice

Sex-specific associations between lipids and cognitive decline in the middle-aged and elderly: a cohort study of Chinese adults